NUT carcinoma: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = NUT carcinoma | |||
| image = [[File:NUT_midline_carcinoma_-_very_high_mag.jpg|alt=Micrograph of NUT carcinoma]] | |||
| caption = Micrograph of NUT carcinoma | |||
| field = [[Oncology]] | |||
| synonyms = NUT midline carcinoma, NMC | |||
| symptoms = [[Respiratory distress]], [[dysphagia]], [[weight loss]], [[fatigue (medical)|fatigue]] | |||
| complications = [[Metastasis]], [[respiratory failure]] | |||
| onset = Typically [[adulthood]], but can occur at any age | |||
| duration = Progressive | |||
| types = | |||
| causes = [[Chromosomal translocation]] involving the [[NUTM1]] gene | |||
| risks = | |||
| diagnosis = [[Biopsy]], [[immunohistochemistry]], [[FISH (fluorescence in situ hybridization)|FISH]], [[RT-PCR]] | |||
| differential = [[Squamous cell carcinoma]], [[adenocarcinoma]], [[lymphoma]] | |||
| prevention = | |||
| treatment = [[Chemotherapy]], [[radiation therapy]], [[surgery]] | |||
| medication = | |||
| prognosis = Poor, with median survival of less than 1 year | |||
| frequency = Very rare | |||
}} | |||
{{Short description|A rare and aggressive form of cancer}} | {{Short description|A rare and aggressive form of cancer}} | ||
'''NUT carcinoma''' (NC), also known as '''NUT midline carcinoma''', is a rare and aggressive form of [[cancer]] that is characterized by the presence of a [[chromosomal translocation]] involving the [[NUTM1 gene]]. This type of carcinoma is most commonly found in the midline structures of the body, such as the [[head and neck]], [[mediastinum]], and other [[thoracic]] regions. | '''NUT carcinoma''' (NC), also known as '''NUT midline carcinoma''', is a rare and aggressive form of [[cancer]] that is characterized by the presence of a [[chromosomal translocation]] involving the [[NUTM1 gene]]. This type of carcinoma is most commonly found in the midline structures of the body, such as the [[head and neck]], [[mediastinum]], and other [[thoracic]] regions. | ||
==Pathophysiology== | ==Pathophysiology== | ||
NUT carcinoma is defined by a specific genetic alteration, typically a translocation between the [[NUTM1 gene]] and other partner genes, most commonly the [[BRD4]] or [[BRD3]] genes. This translocation results in the formation of a fusion protein that disrupts normal cellular processes, leading to uncontrolled cell growth and cancer. | NUT carcinoma is defined by a specific genetic alteration, typically a translocation between the [[NUTM1 gene]] and other partner genes, most commonly the [[BRD4]] or [[BRD3]] genes. This translocation results in the formation of a fusion protein that disrupts normal cellular processes, leading to uncontrolled cell growth and cancer. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with NUT carcinoma often present with rapidly growing masses in the midline structures of the body. Symptoms vary depending on the location of the tumor but may include [[difficulty breathing]], [[dysphagia]], and [[pain]]. Due to its aggressive nature, the disease often progresses quickly, and early diagnosis is crucial. | Patients with NUT carcinoma often present with rapidly growing masses in the midline structures of the body. Symptoms vary depending on the location of the tumor but may include [[difficulty breathing]], [[dysphagia]], and [[pain]]. Due to its aggressive nature, the disease often progresses quickly, and early diagnosis is crucial. | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of NUT carcinoma is confirmed through [[histopathological]] examination and [[immunohistochemistry]]. The presence of the NUTM1 gene rearrangement can be detected using [[fluorescence in situ hybridization]] (FISH) or [[reverse transcription polymerase chain reaction]] (RT-PCR). Immunohistochemical staining for NUT protein is also a key diagnostic tool. | Diagnosis of NUT carcinoma is confirmed through [[histopathological]] examination and [[immunohistochemistry]]. The presence of the NUTM1 gene rearrangement can be detected using [[fluorescence in situ hybridization]] (FISH) or [[reverse transcription polymerase chain reaction]] (RT-PCR). Immunohistochemical staining for NUT protein is also a key diagnostic tool. | ||
==Treatment== | ==Treatment== | ||
Treatment options for NUT carcinoma are limited and often involve a combination of [[surgery]], [[radiation therapy]], and [[chemotherapy]]. Due to the rarity of the disease, there is no standardized treatment protocol, and clinical trials are ongoing to explore new therapeutic approaches. Targeted therapies, such as [[bromodomain inhibitors]], are being investigated as potential treatments. | Treatment options for NUT carcinoma are limited and often involve a combination of [[surgery]], [[radiation therapy]], and [[chemotherapy]]. Due to the rarity of the disease, there is no standardized treatment protocol, and clinical trials are ongoing to explore new therapeutic approaches. Targeted therapies, such as [[bromodomain inhibitors]], are being investigated as potential treatments. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for patients with NUT carcinoma is generally poor due to the aggressive nature of the disease and its tendency to metastasize early. The median survival time is typically less than one year from diagnosis, highlighting the need for early detection and novel therapeutic strategies. | The prognosis for patients with NUT carcinoma is generally poor due to the aggressive nature of the disease and its tendency to metastasize early. The median survival time is typically less than one year from diagnosis, highlighting the need for early detection and novel therapeutic strategies. | ||
==Research== | ==Research== | ||
Ongoing research is focused on understanding the molecular mechanisms underlying NUT carcinoma and developing targeted therapies. The identification of specific genetic alterations has opened new avenues for potential treatments, and clinical trials are crucial for advancing the management of this rare cancer. | Ongoing research is focused on understanding the molecular mechanisms underlying NUT carcinoma and developing targeted therapies. The identification of specific genetic alterations has opened new avenues for potential treatments, and clinical trials are crucial for advancing the management of this rare cancer. | ||
==See also== | |||
== | |||
* [[Carcinoma]] | * [[Carcinoma]] | ||
* [[Chromosomal translocation]] | * [[Chromosomal translocation]] | ||
* [[Oncology]] | * [[Oncology]] | ||
* [[Genetic disorders]] | * [[Genetic disorders]] | ||
[[Category:Rare cancers]] | [[Category:Rare cancers]] | ||
[[Category:Carcinoma]] | [[Category:Carcinoma]] | ||
[[Category:Genetic diseases and disorders]] | [[Category:Genetic diseases and disorders]] | ||
Latest revision as of 04:24, 8 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| NUT carcinoma | |
|---|---|
| |
| Synonyms | NUT midline carcinoma, NMC |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Respiratory distress, dysphagia, weight loss, fatigue |
| Complications | Metastasis, respiratory failure |
| Onset | Typically adulthood, but can occur at any age |
| Duration | Progressive |
| Types | |
| Causes | Chromosomal translocation involving the NUTM1 gene |
| Risks | |
| Diagnosis | Biopsy, immunohistochemistry, FISH, RT-PCR |
| Differential diagnosis | Squamous cell carcinoma, adenocarcinoma, lymphoma |
| Prevention | |
| Treatment | Chemotherapy, radiation therapy, surgery |
| Medication | |
| Prognosis | Poor, with median survival of less than 1 year |
| Frequency | Very rare |
| Deaths | N/A |
A rare and aggressive form of cancer
NUT carcinoma (NC), also known as NUT midline carcinoma, is a rare and aggressive form of cancer that is characterized by the presence of a chromosomal translocation involving the NUTM1 gene. This type of carcinoma is most commonly found in the midline structures of the body, such as the head and neck, mediastinum, and other thoracic regions.
Pathophysiology[edit]
NUT carcinoma is defined by a specific genetic alteration, typically a translocation between the NUTM1 gene and other partner genes, most commonly the BRD4 or BRD3 genes. This translocation results in the formation of a fusion protein that disrupts normal cellular processes, leading to uncontrolled cell growth and cancer.
Clinical Presentation[edit]
Patients with NUT carcinoma often present with rapidly growing masses in the midline structures of the body. Symptoms vary depending on the location of the tumor but may include difficulty breathing, dysphagia, and pain. Due to its aggressive nature, the disease often progresses quickly, and early diagnosis is crucial.
Diagnosis[edit]
Diagnosis of NUT carcinoma is confirmed through histopathological examination and immunohistochemistry. The presence of the NUTM1 gene rearrangement can be detected using fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR). Immunohistochemical staining for NUT protein is also a key diagnostic tool.
Treatment[edit]
Treatment options for NUT carcinoma are limited and often involve a combination of surgery, radiation therapy, and chemotherapy. Due to the rarity of the disease, there is no standardized treatment protocol, and clinical trials are ongoing to explore new therapeutic approaches. Targeted therapies, such as bromodomain inhibitors, are being investigated as potential treatments.
Prognosis[edit]
The prognosis for patients with NUT carcinoma is generally poor due to the aggressive nature of the disease and its tendency to metastasize early. The median survival time is typically less than one year from diagnosis, highlighting the need for early detection and novel therapeutic strategies.
Research[edit]
Ongoing research is focused on understanding the molecular mechanisms underlying NUT carcinoma and developing targeted therapies. The identification of specific genetic alterations has opened new avenues for potential treatments, and clinical trials are crucial for advancing the management of this rare cancer.
